Department of Nephrology, Germans Trias i Pujol University Hospital, Autonomous University of Barcelona, Barcelona, Spain.
Pharmacology. 2011;87(3-4):161-8. doi: 10.1159/000324311. Epub 2011 Mar 4.
BACKGROUND/AIMS: Statins are prescribed in kidney transplant recipients in order to manage dyslipidemia, a common complication in these patients. The efficacy of statins in reducing cholesterol levels has been accompanied by pleiotropic effects. Fifty-four kidney transplant patients were included in the present study, the objective of which was to ascertain the effect of 12 weeks of atorvastatin therapy (10 mg/day) on the patients' lipid profile, renal function, markers of inflammation and plasma peptide profile.
Biochemical variables were determined with a routine clinical laboratory analyzer, and the proteomic approach was based on magnetic particle-assisted sample processing coupled to mass spectrometry readout.
Atorvastatin therapy improved the lipid profile of patients and caused significant changes in their plasma peptide profile; peptides with m/z 1063 and 1898 decreased after treatment and were identified as fragments derived from molecules involved in vascular inflammation, i.e. high-molecular-weight kininogen and complement factor C4, respectively.
These findings may contribute to the growing body of evidence of the anti-inflammatory actions attributed to statins, by which these drugs could improve these patients' clinical status.
背景/目的:他汀类药物被开给肾移植受者,以治疗这些患者常见的血脂异常并发症。他汀类药物降低胆固醇水平的功效伴随着多种有益作用。本研究纳入了 54 名肾移植患者,旨在确定阿托伐他汀治疗(10 毫克/天) 12 周对患者血脂谱、肾功能、炎症标志物和血浆肽谱的影响。
使用常规临床实验室分析仪测定生化变量,蛋白质组学方法基于磁珠辅助样品处理与质谱读取相结合。
阿托伐他汀治疗改善了患者的血脂谱,并导致其血浆肽谱发生显著变化;治疗后 m/z 值为 1063 和 1898 的肽减少,并被鉴定为分别来自参与血管炎症的分子的片段,即高分子量激肽原和补体因子 C4。
这些发现可能有助于他汀类药物抗炎作用的证据不断增加,这些药物可以改善这些患者的临床状况。